secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0001628280-25-001672
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion provides FY2025 expense guidance at J.P. Morgan Conference
-------------------------------------------------------------------

- R&D expenses expected $55M to $65M for FY2025.
- SG&A expenses expected $160M to $170M for FY2025.
- Total operating expenses expected $215M to $235M for FY2025.
- Guidance announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/0001628280-25-001672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/espr-20250115.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer